← Leaderboards
Thomas McGowan Keck
Rowan University
$2,182,985
Attributed
$3,507,827
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $884K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,507,827 · 4
By mechanism
T34$1,832,643 · 1
R01$1,138,608 · 1
R21$428,000 · 1
R03$108,576 · 1
Top collaborators
- Nathaniel V Nucci4 shared
- Comfort Ahenkan Boateng2 shared
- Bradford D Fischer1 shared
Most similar at Rowan University
Same institution · by research overlap
- Mark Randa$800,096
- Alison Krufka$800,096
- Brian W Roberts$769,304
- Jennifer Kadlowec$108,000
- Manoj Kumar Pandey$821,902
Others in their field
Other Emerging Leaders on “Training”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$73,910,854
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Bambra Strokes · Ppd Development Lp$65,000,267
- Martha Hering · Westat, Inc.$57,098,843
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Susan M Landau · University Of California Berkeley$47,252,026
Research focus
TrainingMediatingBehavioralAgonistInnovationExperimental StudyAddictionDosePharmaceutical PreparationsLigandsRecruitSignal TransductionFoodSide EffectAmidesPharmacotherapyReceptorBehavior TestDesignAffinityIn VitroAffectGrowthFellowship
Grant awards (10)
U-Rise at Rowan University$499,661
T34 · FY2025 · GM
Combination drug therapy to treat pain with minimal or no abuse potential and side-effects$374,783
R01 · FY2025 · DA · contact PI
U-Rise at Rowan University$494,995
T34 · FY2024 · GM
Combination drug therapy to treat pain with minimal or no abuse potential and side-effects$374,783
R01 · FY2024 · DA · contact PI
U-Rise at Rowan University$494,995
T34 · FY2023 · GM
Combination drug therapy to treat pain with minimal or no abuse potential and side-effects$389,042
R01 · FY2023 · DA · contact PI
U-Rise at Rowan University$342,992
T34 · FY2022 · GM
Low-Efficacy Dopamine D4 Receptor Partial Agonists for Cocaine Addiction$226,500
R21 · FY2021 · DA
Low-Efficacy Dopamine D4 Receptor Partial Agonists for Cocaine Addiction$201,500
R21 · FY2020 · DA
Abuse liability and anti-addiction potential of the atypical mu opioid receptor agonist IBNtxA$108,576
R03 · FY2017 · DA · contact PI